



SUMMARY

[00011a] In one aspect, the present disclosure provides a compound having Formula **I-A**:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

A is:



E is a carbon atom and == is a double bond; or

E is a -C(H)- and == is a single bond; or

E is a nitrogen atom and $\equiv$ is a single bond;

X^1 , X^2 , and X^3 are each independently selected from the group consisting of $-\text{CR}^8=$ and $-\text{N}=\text{}$;

R^{1a} and R^{1b} taken together with the carbon atom to which they are attached form a spirocyclobutyl, if present, then

- i) E is a carbon atom and $\equiv$ is a double bond or E is a $-\text{C}(\text{H})-$ and $\equiv$ is a single bond; and/or
- ii) R^{2a} is a halogen; or

R^{1a} and R^{1b} taken together with the carbon atom to which they are attached form a spirooxetanyl;

R^2 is selected from the group consisting of $-\text{NO}_2$, $-\text{SO}_2\text{CH}_3$, and $-\text{SO}_2\text{CF}_3$;

R^{2a} is selected from the group consisting of hydrogen and halogen;

R^3 is selected from the group consisting of hydrogen, $-\text{CN}$, $-\text{C}\equiv\text{CH}$, and $-\text{N}(\text{R}^{4a})(\text{R}^{4b})$;

R^{4a} is selected from the group consisting of optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, heterocyclo, heteroalkyl, (cycloalkyl)alkyl, and (heterocyclo)alkyl;

R^{4b} is selected from the group consisting of hydrogen and C_{1-4} alkyl;

and

R^8 is selected from the group consisting of hydrogen and halogen.

[00011b] In another aspect, the present disclosure provides a pharmaceutical composition comprising the compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

[00011c] In another aspect, the present disclosure provides a use of the compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating a hyperproliferative disease.


[00011d] In another aspect, the present disclosure provides a use of the pharmaceutical composition of the disclosure in the manufacture of a medicament for treating a hyperproliferative disease.

[00011e] In another aspect, the present disclosure provides a kit comprising the compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, and instructions for administering the compound, or a pharmaceutically acceptable salt or solvate thereof, to a patient having a hyperproliferative disease.

[0012] In one example, the present disclosure provides compounds represented by any one of Formulae **I-A** or **I-VIII**, below, and the pharmaceutically acceptable salts and


What is Claimed Is:

1. A compound having Formula **I-A**:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

A is:



E is a carbon atom and $\equiv$ is a double bond; or

E is a -C(H)- and $\equiv$ is a single bond; or

E is a nitrogen atom and $\equiv$ is a single bond;

X^1 , X^2 , and X^3 are each independently selected from the group consisting of -CR⁸= and -N=;

R^{1a} and R^{1b} taken together with the carbon atom to which they are attached form a spirocyclobutyl, if present, then

- i) E is a carbon atom and $\equiv$ is a double bond or E is a -C(H)- and $\equiv$ is a single bond; and/or

- ii) R^{2a} is a halogen; or


R^{1a} and R^{1b} taken together with the carbon atom to which they are attached form a spirooxetanyl;

R^2 is selected from the group consisting of -NO₂, -SO₂CH₃, and -SO₂CF₃;


R^{2a} is selected from the group consisting of hydrogen and halogen;

R⁸ is selected from the group consisting of hydrogen and halogen.

3. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having Formula I:




- 111 -




wherein Y is -O-.

5. The compound of claims 1 or 3, or a pharmaceutically acceptable salt or solvate thereof, having Formula **III**:



wherein Y selected from the group consisting of -CH₂- and -O-.


6. The compound of claims 1 or 3, or a pharmaceutically acceptable salt or solvate thereof, having Formula **IV**:



IV,

wherein Y selected from the group consisting of -CH₂- and -O-.


7. The compound of claims 1 or 2, or a pharmaceutically acceptable salt or solvate thereof, having Formula **V**:



V,

wherein Y is -O-.

8. The compound of claim 7, or a pharmaceutically acceptable salt or solvate thereof, having Formula **VII**:



VII.


9. The compound of any one of claims 1, 2, 7 or 8, or a pharmaceutically acceptable salt or solvate thereof, wherein X^1 , X^2 , and X^3 are each $-\text{CH}=\text{}$.
10. The compound of any one of claims 1, 2, 7 or 8, or a pharmaceutically acceptable salt or solvate thereof, wherein X^1 is $-\text{CF}=\text{}$, and X^2 and X^3 are each $-\text{CH}=\text{}$.
11. The compound of any one of claims 1, 2, 7 or 8, or a pharmaceutically acceptable salt or solvate thereof, wherein X^1 and X^3 are each $-\text{CH}=\text{}$, and X^2 is $-\text{CF}=\text{}$.
12. The compound of any one of claims 1, 2, 7 or 8, or a pharmaceutically acceptable salt or solvate thereof, wherein X^1 and X^2 are each $-\text{CH}=\text{}$, and X^3 is $-\text{CF}=\text{}$.
13. The compound of any one of claims 1, 2, 7 or 8, or a pharmaceutically acceptable salt or solvate thereof, wherein X^1 is $-\text{N}=\text{}$, and X^2 and X^3 are each $-\text{CH}=\text{}$.
14. The compound of any one of claims 1, 2, 7 or 8, or a pharmaceutically acceptable salt or solvate thereof, wherein X^1 and X^3 are each $-\text{CH}=\text{}$, and X^2 is $-\text{N}=\text{}$.
15. The compound of any one of claims 1, 2, 7 or 8, or a pharmaceutically acceptable salt or solvate thereof, wherein X^1 and X^2 are each $-\text{CH}=\text{}$, and X^3 is $-\text{N}=\text{}$.

16. The compound of any one of claims 5, 6 and 8-15, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is -O-.


17. The compound of any one of claims 5, 6 and 8-16, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is -CH₂-.

18. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt or solvate thereof, wherein R² is -NO₂.


19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{4a} is selected from the group consisting of:




20. The compound of claims 1-19, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{4a} is selected from the group consisting of:




21. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, selected from one or more compounds selected from:




,




,




,




,



,



,



22. A pharmaceutical composition comprising the compound of any one of claims 1-21, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

23. Use of the compound of any one of claims 1-21, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating a hyperproliferative disease.

24. The use of claim 23, wherein the hyperproliferative disease is cancer.

25. The use of claim 24, wherein the cancer is selected from one or more of adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia,

acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T cell leukemia/lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma,, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor,, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer,, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma,

metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, preimary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor and Wilms' tumor.

26. The use of claim 24, wherein the cancer is selected from the group consisting of acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mixed lineage leukaemia, NUT-midline carcinoma, multiple myeloma, small cell lung cancer, neuroblastoma, Burkitt's lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, and breast cancer.

27. The use of any one of claims 23-26, wherein a second therapeutic agent useful in the treatment of the disease is to be administered.

28. Use of the pharmaceutical composition of claim 22 in the manufacture of a medicament for treating a hyperproliferative disease.

29. The use of claim 28, wherein the hyperproliferative disease is cancer.

30. The use of claim 29, wherein the cancer is selected from one or more of adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T cell leukemia/lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma,, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor,, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma,

intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer,, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, preimary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor and Wilms' tumor.

31. The use of claim 28, wherein the cancer is selected from the group consisting of acute monocytic leukemia, acute myelogenous leukemia, chronic

myelogenous leukemia, chronic lymphocytic leukemia, mixed lineage leukaemia, NUT-midline carcinoma, multiple myeloma, small cell lung cancer, neuroblastoma, Burkitt's lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, and breast cancer.

32. A kit comprising the compound of any one of claims 1-21, or a pharmaceutically acceptable salt or solvate thereof, and instructions for administering the compound, or a pharmaceutically acceptable salt or solvate thereof, to a patient having a hyperproliferative disease.

33. The kit of claim 32, wherein the hyperproliferative disease is cancer.

34. The kit of claim 33, wherein the cancer is selected from one or more of adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T cell leukemia/lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma,, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor,, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid

cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, preimary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, stomach cancer, T-cell

lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor and Wilms' tumor.

35. The kit of claim 33, wherein the cancer is selected from the group consisting of acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mixed lineage leukemia, NUT-midline carcinoma, multiple myeloma, small cell lung cancer, neuroblastoma, Burkitt's lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, and breast cancer.

36. The kit of any one of claims 32-35 further comprising one or more additional therapeutic agents.